Abstract
Given the significant lack of effective therapies for malignant pleural mesothelioma (MPM), Tumor Treating Fields (TTFields) was made available for use under an FDA-approved Humanitarian Device Exemption (HDE) protocol in 2019. In the phase 2 STELLAR study, a 68% median device usage rate (16.3 hours/day) was reported for MPM patients treated with TTFields along with platinum-based chemotherapy in the first 3 months. However, there is no reported real-world usage rate of TTFields for unresectable MPM to date and patterns of use may differ in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
